Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amplia Therapeutics Ltd. ( (AU:ATX) ) has issued an update.
Amplia Therapeutics Ltd. presented interim data from its ACCENT trial at the AACR annual meeting, showcasing the promising efficacy of its FAK inhibitor, narmafotinib, in combination with chemotherapy for advanced pancreatic cancer. The data indicates that narmafotinib is well tolerated and shows better outcomes compared to chemotherapy alone, with a higher disease control rate and longer median duration on trial. This development could enhance Amplia’s positioning in the oncology market and provide new hope for stakeholders involved in pancreatic cancer treatment.
More about Amplia Therapeutics Ltd.
Amplia Therapeutics Ltd. is a biotechnology company focused on developing treatments for cancer. Its primary product, narmafotinib (AMP945), is a FAK inhibitor targeting pancreatic cancer, with Fast-Track and Orphan Drug Designation from the US FDA.
YTD Price Performance: -14.63%
Average Trading Volume: 23,462
Technical Sentiment Signal: Buy
Current Market Cap: $12.63M
For an in-depth examination of ATX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue